Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America
Resumen:
PURPOSE Multiple myeloma (MM) is a highly heterogeneous, incurable disease most frequently diagnosed in the elderly. Therefore, data on clinical characteristics and outcomes in the very young population are scarce. PATIENTS AND METHODS Weanalyzed clinical characteristics, response to treatment, and survival in 103 patients with newly diagnosed MMage40 yearsoryoungercomparedwith256 patients age 41-50 years and 957 patients age 51 years or older. RESULTS There were no statistical differences in sex, isotype, International Scoring System, renal involvement, hypercalcemia, anemia, dialysis, bony lesions, extramedullary disease, and lactate dehydrogenase (LDH). The most used regimen in young patients was cyclophosphamide, bortezomib, dexamethasone, followed by cyclophosphamide, thalidomide, dexamethasone and bortezomib, thalidomide, dexamethasone. Ofthepatients age40 yearsoryounger, only 53% received autologous stem-cell transplant (ASCT) and 71.1% received maintenance. There were no differences in overall survival (OS) in the three patient cohorts. In the multivariate analysis, only high LDH, high cytogenetic risk, and ASCT were statistically associated with survival. CONCLUSION In conclusion, younger patients with MM in Latin America have similar clinical characteristics, responses, and OS compared with the elderly.
| 2023 | |
|
PERSONA DE MEDIANA EDAD PROTOCOLOS DE QUIMIOTERAPIA COMBINADA ANTINEOPLÁSICA BORTEZOMIB CICLOFOSFAMIDA DEXAMETASONA MIELOMA MÚLTIPLE PRONÓSTICO TALIDOMIDA RESULTADO DEL TRATAMIENTO USOS TERAPÉUTICOS QUIMIOTERAPIA EPIDEMIOLOGÍA |
|
| Inglés | |
| Universidad de la República | |
| COLIBRI | |
| https://hdl.handle.net/20.500.12008/53300 | |
| Acceso abierto | |
| Licencia Creative Commons Atribución (CC - By 4.0) |
| Sumario: | Humberto Martinez-Cordero Honoraria: Janssen, Sanofi, Bristol Myers Squibb/Celgene, Takeda Consulting orAdvisoryRole: Janssen, Sanofi,Bristol MyersSquibb/Celgene, Takeda Travel, Accommodations, Expenses: Sanofi Camila Peña Honoraria: Janssen Consulting or Advisory Role: Janssen Travel, Accommodations, Expenses: Varifarma Cecilia Beltran Consulting or Advisory Role: Takeda Travel, Accommodations, Expenses: Janssen, Takeda Javiera Donoso Honoraria: Janssen Oncology Consulting or Advisory Role: Janssen Oncology Hern´ an L´ opez-Vidal Consulting or Advisory Role: Janssen Oncology, Pfizer, AbbVie Speakers’ Bureau: Janssen Oncology Travel, Accommodations, Expenses: Janssen Oncology, Pfizer Macarena Alejandra Roa Salinas Honoraria: AbbVie, AstraZeneca, Tecnofarma Consulting or Advisory Role: Janssen, Takeda, Tecnofarma Travel, Accommodations, Expenses: Roche Pablo Soto Travel, Accommodations, Expenses: Janssen Paola Ochoa Honoraria: Janssen, Sanofi Consulting or Advisory Role: Sanofi, Janssen Travel, Accommodations, Expenses: Janssen Patricio Duarte Consulting or Advisory Role: Janssen, Sanofi, Takeda Speakers’ Bureau: Sanofi Travel, Accommodations, Expenses: Sanofi Guillermina Remaggi Consulting or Advisory Role: Janssen-Cilag, Sanofi,Pfizer Speakers’ Bureau: Janssen Travel, Accommodations, Expenses: Janssen, Sanofi Claudia Shanley Honoraria: Takeda Consulting or Advisory Role: Sanofi, AbbVie, Janssen Travel, Accommodations, Expenses: Janssen Sergio Lopresti Honoraria: Janssen Oncology Dorotea Fantl Speakers’ Bureau: Janssen, Takeda, Sanofi, Amgen Research Funding: Janssen, Takeda, Helsinn Therapeutics, Sanofi, Roche Travel, Accommodations, Expenses: Janssen, Sanofi Guillermo Quintero Consulting or Advisory Role: Janssen Oncology, Pfizer, Takeda, Sanofi Travel, Accommodations, Expenses: AbbVie, Amgen, Janssen Oncology, Roche David Gomez-Almaguer Consulting or Advisory Role: Janssen, Takeda, Teva, BMS. Speakers’Bureau:Bristol MyersSquibb(Mexico),AbbVie,Novartis,Janssen, Amgen, Takeda Luis Antonio Salazar Honoraria: Janssen, AbbVie, AstraZeneca Consulting or Advisory Role: AstraZeneca, Janssen Travel, Accommodations, Expenses: Janssen Mar´ ıa Cynthia Fuentes-Lacouture Honoraria: Fresenius Kabi BioSimiliars Travel, Accommodations, Expenses: Janssen Mario Pereira Honoraria: Novartis, Amgen, Janssen, Pint Pharma Consulting or Advisory Role: Novartis Travel, Accommodations, Expenses: AbbVie. Jule Vasquez Honoraria: Janssen, Roche Consulting or Advisory Role: Janssen, AbbVie Research Funding: Roche (Inst) Travel, Accommodations, Expenses: Janssen, AbbVie Elo´ ısa Riva Honoraria: Sanofi, Janssen, AbbVie/Genentech Research Funding: Sebia (Inst) Travel, Accommodations, Expenses: Roemmers, Janssen, Sanof |
|---|
